Literature DB >> 19041124

Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1.

Emily Berry1, Jennifer L Hardt, Jon Clardy, John R Lurain, J Julie Kim.   

Abstract

OBJECTIVE: Endometrial cancer is the most common type of gynecologic cancer in the United States. In this study, we propose that a marine sponge compound, psammaplysene A (PsA) induces apoptosis in endometrial cancer cells through forced nuclear expression of FOXO1.
METHODS: Ishikawa and ECC1 cells were treated with varying doses of PsA. FOXO1 protein localization was observed using immunofluorescent staining of cells. The effects of PsA on cell viability and proliferation were assessed using a cell viability assay and a BrdU incorporation assay respectively. Cell cycle analysis was performed using flow cytometry. To assess the role of FOXO1 in PsA-induced apoptosis, FOXO1 was silenced in ECC1 cells using siRNA technique, and overexpressed in Ishikawa cells using an adenovirus containing FOXO1 cDNAs. Western blots were used to measure levels of FOXO1 and cleaved PARP proteins.
RESULTS: Treatment of both ECC1 and Ishikawa cells with PsA caused an increase in nuclear FOXO1 protein, a dramatic decrease in cell viability of approximately 5-fold (p<0.05) and minimal effect on proliferation. Furthermore, treatment of cells with PsA doubled the percentage of cells in the G2/M phase (p<0.05). PsA induced apoptosis in endometrial cancer cells. When FOXO1 was silenced in ECC1 cells and treated with PsA, the incidence of apoptosis decreased. In addition, overexpression of FOXO1 with PsA treatment increased apoptosis.
CONCLUSIONS: Increasing nuclear FOXO1 function is important for the induction of apoptosis of endometrial cancer cells by PsA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041124      PMCID: PMC2662924          DOI: 10.1016/j.ygyno.2008.10.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  39 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  The psammaplysenes, specific inhibitors of FOXO1a nuclear export.

Authors:  Frank C Schroeder; Tweeny R Kau; Pamela A Silver; Jon Clardy
Journal:  J Nat Prod       Date:  2005-04       Impact factor: 4.050

3.  Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin.

Authors:  B A Lessey; A O Ilesanmi; A J Castelbaum; L Yuan; S G Somkuti; K Chwalisz; P G Satyaswaroop
Journal:  J Steroid Biochem Mol Biol       Date:  1996-09       Impact factor: 4.292

4.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

6.  FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis.

Authors:  Mani Alikhani; Zoubin Alikhani; Dana T Graves
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

7.  Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1.

Authors:  W H Biggs; J Meisenhelder; T Hunter; W K Cavenee; K C Arden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

8.  Hormonal control of proliferation in the Ishikawa endometrial adenocarcinoma cell line.

Authors:  J D Croxtall; M G Elder; J O White
Journal:  J Steroid Biochem       Date:  1990-05       Impact factor: 4.292

9.  Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile.

Authors:  J Fanning; M C Evans; A J Peters; M Samuel; E R Harmon; J S Bates
Journal:  Gynecol Oncol       Date:  1989-03       Impact factor: 5.482

10.  Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells.

Authors:  X Jin; D R Gossett; S Wang; D Yang; Y Cao; J Chen; R Guo; R K Reynolds; J Lin
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more
  7 in total

Review 1.  Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.

Authors:  Brahma N Singh; Hongyuan Zhou; Jinping Li; Tracy Tipton; Bin Wang; Guo Shao; E Nickolas Gilbert; Qiang Li; Shi-Wen Jiang
Journal:  Future Oncol       Date:  2011-12       Impact factor: 3.404

Review 2.  Recently confirmed apoptosis-inducing lead compounds isolated from marine sponge of potential relevance in cancer treatment.

Authors:  Magbubah Essack; Vladimir B Bajic; John A C Archer
Journal:  Mar Drugs       Date:  2011-09-20       Impact factor: 6.085

3.  miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1.

Authors:  Yanhua Liu; Jing Jiang; Xinjing Wang; Fei Zhai; Xiaoxing Cheng
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

Review 4.  Sponges: A Reservoir of Genes Implicated in Human Cancer.

Authors:  Helena Ćetković; Mirna Halasz; Maja Herak Bosnar
Journal:  Mar Drugs       Date:  2018-01-10       Impact factor: 5.118

5.  Forkhead transcription factor 1 inhibits endometrial cancer cell proliferation via sterol regulatory element-binding protein 1.

Authors:  Yifang Zhang; Lili Zhang; Hengzi Sun; Qingtao Lv; Chunping Qiu; Xiaoxia Che; Zhiming Liu; Jie Jiang
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

Review 6.  Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies.

Authors:  Rajeev K Singla; Sahar Behzad; Johra Khan; Christos Tsagkaris; Rupesh K Gautam; Rajat Goyal; Hitesh Chopra; Bairong Shen
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

Review 7.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.